THVD-201
DrugCombination of Tolterodine 2mg and Pilocarpine 9mg
NCT Number: NCT02485067
The primary purpose of this study is to assess the efficacy and safety of THVD-201(Combination of tolterodine and pilocarpine) in patients with Overactive bladder during the period of treatment, 12 weeks.
This study also includes an open label extension period of an additional 12 weeks following the treatment to assess long-term efficacy and safety of THVD-201 in patients with Overactive bladder.
Looking for future studies?
Notify Me20 year–85 year
All sexes
Interventional
Phase 3
Inje University Busan Paik Hospital, Busan, South Korea
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Combination of Tolterodine 2mg and Pilocarpine 9mg
Tolterodine 2mg
Time frame: 12 weeks
The change of Mean daily micturition frequency between 0 and 12 weeks
Time frame: 12 weeks
Time frame: 24 weeks
The change of Mean daily micturition frequency between 0 and 24 weeks
Time frame: 12 weeks
The change of Mean daily Incontinence frequency between 0 and 12 weeks
Time frame: 24 weeks
The change of Mean daily Incontinence frequency between 0 and 24 weeks
Time frame: 12 weeks
The change of Mean daily Urgency frequency between 0 and 12 weeks
Time frame: 24 weeks
The change of Mean daily Urgency frequency between 0 and 24 weeks
Time frame: 12 weeks
The change of Mean daily Nocturia frequency between 0 and 12 weeks
Time frame: 24 weeks
The change of Mean daily Nocturia frequency between 0 and 24 weeks
Time frame: 12 weeks
The change of Mean daily Micturition volume between 0 and 12 weeks
Time frame: 24 weeks
The change of Mean daily Micturition volume between 0 and 24 weeks
Time frame: 12 weeks
The change of the Score between 0 and 12 weeks
Time frame: 24 weeks
The change of the Score between 0 and 24 weeks
Time frame: 12 weeks
The change of the Score between 0 and 12 weeks
Time frame: 24 weeks
The change of the Score between 0 and 24 weeks
Time frame: 12 weeks
The change of the Score between 0 and 12 weeks
Time frame: 24 weeks
The change of the Score between 0 and 24 weeks
Time frame: 12 weeks
The change of the Score between 0 and 12 weeks
Time frame: 24 weeks
The change of the Score between 0 and 24 weeks
SK Chemicals Co., Ltd.
Industry
Multicenter, Randomized, Double-blind, Parallel, Active Control, Phase III Clinical Study to Assess the Efficacy and Safety of THVD-201 in Patients With Overactive Bladder Including an Open-label, Extension Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05799313
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Cleveland, Ohio, United States
View Trial DetailsNCT05557279
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Maywood, Illinois, United States
View Trial DetailsNCT06198439
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Houston, Texas, United States
View Trial DetailsNCT06206512
Cardiovascular Diseases, Female Urogenital Diseases
Dallas, Texas, United States
View Trial Details